期刊文献+

某三甲医院万古霉素临床用药安全性评价

下载PDF
导出
摘要 目的分析整合万古霉素的血药浓度数据,为临床合理使用万古霉素提供依据和指导。方法对某院2020年全年使用万古霉素并进行血药浓度监测的128例患者进行回顾性分析和总结,分析万古霉素血药浓度与年龄、溶媒量、肾功能的关系以及溶媒量、药物浓度对患者肾功能的影响。结果128例患者监测万古霉素血药浓度共239例次,其中126例次的患者(52.72%)万古霉素的血药浓度在治疗窗范围(10~20μg/ml)内。60~70岁患者的血药浓度均值约为27.89μg/ml,已达到中毒浓度,而<60岁和>70岁患者的血药浓度均值都在正常范围内。肾功能轻度损害组的患者和肾功能中重度损害组的患者在使用万古霉素前后的血肌酐及尿素氮差异无统计学意义(P>0.05),但肾功能正常组患者在使用万古霉素前后的血肌酐及尿素氮比较差异均有统计学意义(P<0.05);单次给药浓度为0.5%组用药前后肌酐清除率比较差异有统计学意义(P<0.05),单次给药浓度>0.5%组用药前后的尿素氮比较差异有统计学意义(P<0.05)。结论年龄、基础肾功能、溶媒量均会影响万古霉素的血药浓度,也存在肾损伤的风险。在连续使用万古霉素期间应该加强血药浓度监测频率,临床药师应该加强药学监护,并且指导临床合理用药。
作者 徐江 夏宗玲
出处 《中国处方药》 2023年第7期83-87,共5页 Journal of China Prescription Drug
  • 相关文献

参考文献9

二级参考文献51

  • 1Yoshiyama Y, Yazaki T, Wong PC, et al. The effect of fosfomycin on glycopeptide antibiotic-induced nephrotoxicity inrats. J Infect Chemother,2001,7:243-246.
  • 2Toyoguchi T, Nakagawa Y. Nephrotoxicity and drug interaction of vancomycin. Nippon Yakurigaku Zasshi,1996,107:225-235.
  • 3Cavalcanti AB, Goncalves AR, Almeida CS, et al. Teicoplanin versus vancomycin for proven or suspected infection.Cochrane Database Syst Rev,2010,16:CD007022.
  • 4Vazquez L, Encinas MP, Morin LS, et al Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica, 1999,84:231-236.
  • 5Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med,2010,38:1802-1808.
  • 6Pletz MW, Burkhardt O, Welte T. Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy. Eur J Med Res,2010,15: 507-513.
  • 7Rybak M,Lomaestro B,Rotschafer JC,et al.Therapeutic monitoring of vancomycin in adult patients;a consensus review of the American Society of Health-System Pharmacists,the Infectious Diseases Society of America,and the Society of Infectious Diseases Pharmacists[J].Am J Health Syst Pharm,2009;66:82-98.
  • 8Murphy JE,Gillespie DE,Bateman CV.Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters[J].Am J Health Syst Pharm,2006;63:2365-2370.
  • 9Tsuji Y,Hiraki Y,Mizoguchi A,et al.Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods[J].J Clin Pharm Ther,2009;34:465-472.
  • 10Fernández de Gatta Mdel M,Santos Buelga D,Sánchez Navarro A,et al.Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokinetic/ pharmacodynamic analysis[J].Clin Pharmacokinet,2009;48:273-280.

共引文献801

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部